Current and Future Approaches to Inhibitor Management and Aversion

ABSTRACT

Immune tolerance induction (ITI) is the most common approach used to eliminate inhibitors that develop in hemophilia A patients following exposure to factor (F) VIII therapy. ITI generally requires ongoing long-term exposure to factor replacement therapy using FVIII or FIX. Although plasma-derived products have been the mainstay of ITI therapy in the past, recent data indicate that high-purity (i.e., recombinant) rFVIII products are probably equally effective. For patients who have failed to respond to ITI treatment, or for those at high risk to do so, immunosuppressive therapy may be helpful. Rituximab has demonstrated a possible clinical benefit in hemophilic and nonhemophilic patients developing FVIII inhibitors, but benefit in those with congenital hemophilia and inhibitors has not been established and more extensive clinical studies are needed. More recently, research on reducing the incidence of inhibitor development has included mutagenizing key epitopes of the FVIII antigenic molecule to alter its immunogenicity without affecting biological activity, as well as induction of tolerance by gene therapy with immunodominant A2 and C2 domains of FVIII presented by B cells as immunoglobulin fusion proteins.

KEYWORDS

Immune tolerance induction (ITI) - immunosuppressive therapy - rituximab - congenital hemophilia - gene therapy

REFERENCES

• 1 Leissinger C A. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.  Am J Hematol. 2004;  77 187-193
• 2 Leissinger C, Wulff K, Abdou A. Inhibitor prevalence and association with morbidity in severe hemophilia A patients.  Blood. 2001;  98 535 (abst)
• 3 Ananyeva N, Khrenov A, Darr F et al.. Treating haemophilia A with recombinant blood factors: a comparison.  Expert Opin Pharmacother. 2004;  5 1061-1070
• 4 Mariani G, Siragusa S, Kroner B L. Immune tolerance induction in hemophilia A: a review.  Semin Thromb Hemost. 2003;  29 69-76
• 5 DiMichele D M, Kroner B L. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors.  Thromb Haemost. 2002;  87 52-57
• 6 Kroner B L. Comparison of the international immune tolerance registry and the North American immune tolerance registry.  Vox Sang. 1999;  77(suppl 1) 33-37
• 7 Smith M P, Spence K J, Waters E L et al.. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution.  Thromb Haemost. 1999;  81 35-38
• 8 Rocino A, de Biasi R. Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients.  Vox Sang. 1999;  77(suppl 1) 65-69
• 9 Mauser-Bunschoten E P, van der Bom J G, Bongers M et al.. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A.  Haemophilia. 2001;  7 364-368
• 10 Hay C R, Doughty H I, Savidge G F. Continuous infusion of factor VIII for surgery and major bleeding.  Blood Coagul Fibrinolysis. 1996;  7(suppl 1) S15-S19
• 11 Borel-Derlon A, Lambert T, Rocino A et al.. Retrospective assessment of immune tolerance induction with recombinate rAHF, a highly purified, full-length recombinant FVIII, in hemophilia A patients with inhibitors.  Haemophilia. 2004;  10(suppl 3) 53-66
• 12 Kobrinsky N L, Sjolander D E, Moser D K, Stegman D A. Ablation of hemophilic FVIII inhibitors with FVIII priming, cyclophosphamide immune suppression, and rapid tapering of FVIII immune tolerance.  Am J Hematol. 2004;  76 180-184
• 13 Patel K, Berman J, Ferber A, Caro J. Refractory autoimmune thrombocytopenic purpura treatment with rituximab.  Am J Hematol. 2001;  67 59-60
• 14 Wiestner A, Cho H J, Asch A S et al.. Rituximab in the treatment of acquired factor VIII inhibitors.  Blood. 2002;  100 3426-3428
• 15 Mathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.  Br J Haematol. 2004;  125 366-368
• 16 Carcao M, St Louis J, Lacroix S, Stain A M, Rivard G. Association of Hemophilia Clinic Directors of Canada . Rituximab for congenital hemophiliacs with inhibitors: a Canadian experience.  Haemophilia. 2004;  10(suppl 3) 53-66
• 17 Eisenberg R, Looney R J. The therapeutic potential of anti-CD20 “What do B-cells do?”.  Clin Immunol. 2005;  117 207-213
• 18 Qian J, Collins M, Sharpe A H, Hoyer L W. Prevention and treatment of factor VIII inhibitors in murine hemophilia A.  Blood. 2000;  95 1324-1329
• 19 Reipert B M, Sasgary M, Ahmad R U et al.. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.  Thromb Haemost. 2001;  86 1345-1352
• 20 Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A.  Blood. 2001;  97 2750-2757
• 21 Hausl C, Ahmad R U, Schwartz H P et al.. Preventing re-stimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders.  Blood. 2004;  104 115-122
• 22 Villard S, Lacroix-Desmazess S, Kieber-Emmons T et al.. Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor.  Blood. 2003;  102 949-952
• 23 Parker E T, Healey J F, Barrow R T, Craddock H N, Lollar P. Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope.  Blood. 2004;  104 704-710
• 24 Purohit V S, Ramani K, Sarkar R, Kazazian Jr H H, Balasubramanian S V. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.  J Biol Chem. 2005;  280 17593-17600
• 25 Rawle F, Labelle A, Davie E, Pratt K, Lillicrap D. Prevention of anti-FVIII inhibitor formation post protein infusion in hemophilic mice by prior feeding of the FVIII-C2 domain. Paper presented at: Annual Meeting of the American Society of Hemophilia 2004 San Diego, CA;
• 26 Lei T C, Scott D W. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B-cells as Ig fusion proteins.  Blood. 2005;  105 4865-4870
• 27 Von Boehmer H. Mechanisms of suppression by suppressor T cells.  Nat Immunol. 2005;  6 338-344
• 28 O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control.  Nat Med. 2004;  10 801-805
• 29 Samsom J N. Regulation of antigen-specific regulatory T-cell induction via nasal or oral mucosa.  Crit Rev Immunol. 2004;  24 157-177
• 30 Hausl C, Ahmad R U, Sasgary M et al.. High dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.  Blood. 2005;  106 3415-3422